Tabuk

All products

0.1 introduction

0.1 introduction

0.1 introduction

1. what is ethics? what is business ethics?

1. what is pharmacovigilance (pv)?

1.1 definition and concept of pain

1.1 definition and concept of pain

1.1 definition and goals of sedation

1.1 description and definitions

1.1 introduction

1.1 introduction

1.1 introduction to microbiology

1.1 module content

1.1 overview of hemostasis

1.1 respiratory system organs

1.1 respiratory system organs

1.1 what is asthma?

1.1 what is general anesthesia?

1.2 bacteriology

1.2 classification

1.2 epidemiology

1.2 epidemiology (global and local burden)

1.2 global and local burden

1.2 importance of pain management in clinical practice

1.2 lower respiratory tract infections

1.2 sedation vs. general anesthesia

1.2 stages of general anesthesia

1.2 stages of hemostasis

1.2 upper respiratory tract infections

1.3 common pathogenic bacteria

1.3 depth of anesthesia (sedation spectrum)

1.3 epidemiology

1.3 etiology and risk factors

1.3 indications for sedation

1.3 lower respiratory tract infections

1.3 normal physiology

1.4 pathophysiology

1.4 pathophysiology

1.4 pathophysiology of asthma

1.4 physiology & pathophysiology

1.5 etiologies & risk factors

1.5 etiology & risk factors

1.6 diagnosis & clinical presentation

10. to whom do we report?

11. step by step to report the adr?

12. lack of efficacy & quality complaints

13. step by step to report the quality complaint

14. pharmacovigilance tabuk contact information

15. summary video

2. aims of pharmacovigilance

2. what is compliance?

2.1 antibiotic therapy classifications

2.1 classification of seizures and epilepsy syndromes

2.1 clinical assessment: history & symptoms

2.1 clinical presentation

2.1 important definitions

2.1 medical history & risk stratification

2.1 patient evaluation and consent

2.1 physiological aspects of pain

2.1 prevalence and incidence

2.1 the circulatory system

2.1 urinary tract system

2.1 what are anticoagulants?

2.2 cardiovascular system components and functions

2.2 causes of dementia

2.2 etiology of epilepsy

2.2 glycemic goals & hypoglycemia

2.2 mechanism of action (moa) of anticoagulants

2.2 mode of action of antibiotics

2.2 physical exam & lab investigations

2.2 physical examination findings

2.2 risk stratification

2.2 urinary tract infections

2.3 antibiotics stewardship

2.3 anticoagulants route of administration types

2.3 essential diagnostic tests (lung function)

2.3 other diagnostic procedures

2.3 pharmacological approach to glycemic treatment; choice of glucose-lowering therapy

2.3 signs and symptoms

2.4 additional diagnostic tests & differential diagnosis

2.4 antimicrobial resistance

2.4 diagnosis of familial hypercholesterolemia

2.4 indications of anticoagulants

2.4 microbial etiology

2.4 the blood vessels

2.5 antibiotic susceptibility

2.5 arterial blood pressure

2.5 treatment guideline

2.6 consequences of antibiotic use

2.6 factors affecting blood pressure

2.7 pathophysiology of hypertension

3. benefits versus risks

3. why should we comply?

3.1 anatomy and physiology

3.1 classification of antibiotics

3.1 definition of venous thromboembolism (vte)

3.1 focal seizures: neurological evaluation & case videos

3.1 guidelines definitions of blood pressure

3.1 mechanism of action: gaba and nmda pathways

3.1 pathogenesis

3.1 pathophysiology and introduction

3.1 pharmacological treatment

3.1 treatment goals

3.1 type 1 diabetes mellitus

3.1 vital signs and physiological monitoring

3.10 complications

3.10 vte in cancer patients

3.11 evidence-based medicine

3.12 the future of alzheimer’s disease

3.2 definition and pathology

3.2 dopamine movement

3.2 epidemiology of hypertension

3.2 epidemiology of vte

3.2 generalized seizures: neurological examination & case videos

3.2 gina guidelines

3.2 mechanism of action of antibiotics

3.2 pharmacological treatment

3.2 phases & pharmacology of anesthesia

3.2 right-sided infective endocarditis

3.2 sedation depth assessment tools

3.2 type 2 diabetes mellitus

3.3 epidemiology

3.3 etiology and risk factors of vte

3.3 intraoperative management

3.3 non-pharmacological approaches

3.3 non-pharmacological treatment

3.3 personalized treatment of asthma

3.3 status epilepticus: neurological examination

3.3 types of hypertension

3.4 management of older adults

3.4 pathophysiology of vte

3.4 postoperative care

3.4 risk factors

3.4 risk factors of hypertension

3.4 stepwise asthma treatment: adults and adolescents

3.5 clinical presentation of vte (dvt and pe)

3.5 forms and stages

3.5 management of patients with chronic kidney disease (ckd)

3.5 stepwise asthma treatment: children 6–11 years

3.6 children 5 years and younger

3.6 diagnosis and assessment tools

3.6 diagnosis of dvt

3.6 management of diabetes in pregnancy

3.7 clinical presentation and classification

3.7 diagnosis of pe

3.7 non-pharmacological management

3.8 treatment of vte

3.9 medications

3.9 vte in orthopedic surgeries

4. how to ensure compliance

4. understanding pharmacovigilance

4.1 assessment of asthma control

4.1 clinical presentation

4.1 demographics

4.1 familial hypercholesterolemia

4.1 first-generation antiepileptic medications

4.1 ideal properties of inhalational anesthetic agents

4.1 introduction

4.1 mechanisms of action of core sedatives

4.1 microflora of gastrointestinal tract

4.1 overview of atrial fibrillation (af)

4.1 regular monitoring parameters

4.2 asthma exacerbation

4.2 benzodiazepines: midazolam & diazepam

4.2 diabetes mellitus

4.2 environmental risk factors

4.2 epidemiology of af

4.2 factors influencing prognosis

4.2 gastroenteritis

4.2 principles of inhaled anesthetic pharmacokinetics

4.2 second generation antiepileptic medications

4.2 short-term complications of poorly managed diabetes

4.2 skin physiology

4.3 assessment of cv risk

4.3 etiology of af

4.3 genetic risk factors

4.3 inhaled anesthetic agents

4.3 long-term complications of poorly managed diabetes

4.3 non-pharmacological therapy

4.3 skin and skin structure infection (sssi) or skin and soft tissue infection (ssti)

4.4 2019 acc/aha treatment goals

4.4 complications of poorly controlled asthma

4.4 features suggestive of cardioembolic stroke

4.4 take home messages

4.5 assessing stroke and bleeding risk in atrial fibrillation

4.5 dexmedetomidine

4.6 strategies for prevention of stroke in af (spaf)

5. important concepts & definitions

5. what is code of conduct? why is it important?

5.1 2017 acc/aha treatment goals and recommendations

5.1 common complications of anesthesia

5.1 esc guidelines for the management of atrial fibrillation

5.1 guideline overview

5.1 introduction

5.1 monitoring and recovery

5.1 motor symptoms

5.2 managing sedation-related complications

5.2 non-motor symptoms

5.2 preconception, pregnancy, and postpartum care

5.2 skin physiology

5.3 mhra guidance

5.3 pain and nausea control

5.3 skin and skin structure infection (sssi) or skin and soft tissue infection (ssti)

5.3 sympatholytics

5.4 adrenoreceptor blockers

5.4 bacteremia in skin and skin structure infections (sssis)

5.5 bacteremia in endocarditis

5.5 vasodilators

5.6 calcium channel blockers

5.7 renin angiotensin inhibitors

5.8 clinicians perspectives and special people groups

6. why we must report adr?

6.1 bp thresholds and recommendations for treatment and follow up

6.1 complications

6.1 disease stages

6.1 overview of lvt

6.1 pediatric considerations

6.2 advancement of disease stages in correlation with disability

6.2 geriatric considerations

6.2 strategies for lvt detection

6.2 take-home messages

6.3 role of anticoagulants in lvt treatment and prophylaxis

7. interactions with hcps

7. what do we report?

7.1 goal of treatment

7.1 overview of hit

7.1 high blood pressure complications

7.2 risk factors of hit

7.2 therapy options

7.3 general treatment principles

7.3 recent guidelines for hit

7.4 medications

7.4 role of anticoagulants in hit treatment

8. interactions with the public

8. what information should be reported?

8.1 special situations

9. disclosure & transparency

9. when and where to report?

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge

test your knowledge